Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025
Rein Therapeutics (NASDAQ: RNTX), a biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis conditions, has announced its upcoming presentation at The Citizens Life Sciences Conference 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rein Therapeutics (NASDAQ: RNTX), a biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis conditions, has announced its upcoming presentation at The Citizens Life Sciences Conference 2025.
Brian Windsor, Ph.D., who serves as President and Chief Executive Officer, will deliver the presentation on Thursday, May 8, 2025 at 12:00 p.m. EDT in New York, NY.
Interested parties can access the presentation through a live webcast at the company's investor relations website. The recording will remain available for 90 days after the event.
Positive
- Company is developing first-in-class medicines for orphan pulmonary and fibrosis indications, targeting potentially lucrative niche markets
Negative
- None.
Details
News Market Reaction – RNTX
The recorded move for RNTX in the trading session of this news was -4.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the event can be accessed at https://ir.reintx.com/events-presentations. A replay of the webcast will be available for 90 days following the presentation.
About Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis is anticipated to be initiated in the first half of this year. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the
Rein Investor Relations & Media Contact:
Argot Partners
rein@argotpartners.com
212-600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/rein-therapeutics-to-present-at-the-citizens-life-sciences-conference-2025-302443270.html
SOURCE Rein Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.